MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
TherapeuticsMD Operating Cash Flow 2011-2026 | TXMD
Annual Operating Cash Flow TherapeuticsMD
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -159 M | -166 M | -107 M | -76.2 M | -69.1 M | -79 M | -45.5 M | -20.8 M | -12.7 M | -4.97 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.97 M | -166 M | -74 M |
Quarterly Operating Cash Flow TherapeuticsMD
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | -8.7 M | - | -63.8 M | -44.9 M | -17.9 M | - | -103 M | -64.9 M | -38.4 M | - | -129 M | -95.1 M | -39.1 M | - | -115 M | -88.7 M | -38.2 M | - | -78.7 M | -44.6 M | -19.6 M | - | -55.4 M | -38.7 M | -20.5 M | - | -53.5 M | -34.7 M | -19.4 M | - | -62.4 M | -44 M | -19.1 M | - | -30.2 M | -18.8 M | -8.71 M | - | -16 M | -10.7 M | -3.51 M | - | -8.73 M | -5.65 M | -2.45 M | - | -3.08 M | -1.56 M | -761 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -761 K | -129 M | -39.1 M |
Operating Cash Flow of other stocks in the Drug manufacturers industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
-28.2 M | $ 19.0 | -1.35 % | $ 122 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.1 | - | $ 43.6 M | USA |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 5.2 | -3.7 % | $ 1.9 B | Canada |
 |
Aurora Cannabis
ACB
|
-211 M | $ 3.39 | -1.6 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 0.99 | -3.18 % | $ 106 M | Canada |
 |
Harrow Health
HROW
|
43.9 M | $ 34.6 | -1.51 % | $ 1.27 B | USA |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
-42.3 M | $ 4.02 | -3.37 % | $ 259 M | USA |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 7.96 | -1.73 % | $ 408 M | USA |
 |
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.37 | -1.09 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
14.2 M | $ 2.49 | 11.16 % | $ 328 M | USA |
 |
Pacira BioSciences
PCRX
|
189 M | $ 22.08 | -0.88 % | $ 1.02 B | USA |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.34 | -0.19 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.31 | -0.65 % | $ 2.87 M | USA |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
7.91 M | $ 6.46 | -3.0 % | $ 3.99 B | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | Canada |
 |
Veru
VERU
|
-21.7 M | $ 2.36 | -1.56 % | $ 318 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
Viatris
VTRS
|
2.9 B | $ 13.16 | -1.86 % | $ 15.8 B | USA |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
-353 K | $ 0.73 | -2.12 % | $ 3.15 M | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-45.8 M | $ 6.69 | -3.04 % | $ 264 M | USA |
 |
Rockwell Medical
RMTI
|
-659 K | $ 0.96 | -0.73 % | $ 34.5 M | USA |
 |
SCYNEXIS
SCYX
|
-5.28 M | $ 0.9 | -2.12 % | $ 44.9 M | USA |
 |
Solid Biosciences
SLDB
|
-156 M | $ 7.58 | -2.07 % | $ 663 M | USA |
 |
Zomedica Corp.
ZOM
|
-17.6 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
148 K | $ 0.61 | - | $ 2.62 M |  China |